Compare ProShares Ultra Bitcoin ETF (BITU) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bitcoin ETF vs Summit Therapeutics Inc — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.14, while Summit Therapeutics Inc trades at $15.19 (market cap $12.06B). The key difference: Summit Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITU | SMMT | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.41 | $26.98 |
52-Week Low | $8.12 | $12.55 |
Market Cap | — | $12.06B |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITU trades at $9.145, down 1.98% today, with a bearish technical outlook as moving averages signal strong selling pressure. The stock has shown consistent dividend payments, with the latest being $0.02 per share. Recent news highlights concerns over its leveraged structure and volatility decay, impacting investor confidence.
The outlook remains cautious due to weak technical signals and negative sentiment. Risks include high volatility and underperformance in non-bull markets. Analyst consensus leans bearish, with limited fundamental data available to support a positive near-term view.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
